|Mr. Louie Canitano||COO & MD of Light Therapy Products||126.52k||N/A||N/A|
|Mr. Michael Druhan||Pres of Dermatological Services & Products||250k||N/A||N/A|
|Mr. Naman Demaghlatrous BAMA||Pres, CEO & Director||N/A||N/A||N/A|
|C H Freeman||Interim Chief Financial Officer||N/A||N/A||N/A|
|Dr. Daniel A. Kaute||Managing Director of Europe||N/A||N/A||N/A|
|Mr. Scott Naughton||Managing Director of US Operations||N/A||N/A||N/A|
|Mr. Christopher H. Freeman||Sec.||N/A||N/A||N/A|
MedX Health Corp, a medical device and software company, develops, manufactures, and markets skin related screening tools and phototherapy devices for pain relief and tissue repair in Canada, the United States, and internationally. The company offers SIAscopy, a medical device technology used to scan skin for suspicious moles and lesions; phototherapeutic medical devices, which use light energy in lower-level laser and LED to provide treatment for pain and tissue damage in the rehabilitation market; and SIAMETRICS, SIMSYS, and MoleMate, which creates real-time images for physicians and dermatologists to evaluate various types of moles or lesions within seconds. It operates DermSecure telemedicine platform that enables the web-based operation of its SIAscopy scanning technology and allows the company to deploy its technology in networks of third-party locations from which patients' mole and lesion images along with other relevant patient information can be connected to specialist physicians for remote assessment. The company was incorporated in 1999 and is headquartered in Mississauga, Canada.
MedX Health Corp’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.